TOLAZ DT 2.5
TOLAZ DT 5
TOLAZ DT 7.5
TOLAZ DT 10
For the use of a Registered Medical Practitioner or Hospital or a Laboratory only

Abbreviated Prescribing information for **TOLAZ DT** [(**Olanzapine orally disintegrating tablets USP 2.5 mg, 5 mg, 7.5 mg & 10 mg**)] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES Olanzapine is an antipsychotic, antimanic, and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.

INDICATION: It is indicated for treatment of schizophrenia in adults

DOSAGE AND ADMINISTRATION: - As directed by the Physician.

CONTRAINDICATION: Hypersensitivity to the active substance or to any of the excipients listed Patients with known risk for narrow-angle glaucoma.

WARNINGS & PRECAUTIONS: During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored during this period. Also in conditions with: Dementia-related psychosis and/or behavioural disturbances, Parkinson's disease, Neuroleptic Malignant Syndrome (NMS), Hyperglycaemia and diabetes, Lipid alterations, Anticholinergic activity, Hepatic function, Neutropenia, Discontinuation of treatment, QT interval, Thromboembolism, General CNS activity, Seizures, Tardive dyskinesia, Postural hypotension, Sudden cardiac death and for Paediatric population.

DRUG INTERACTIONS: Interaction studies have only been performed in adults. Like 1) Potential Interactions Affecting olanzapine: Induction of CYP1A2- smoking and carbamazepine, Inhibition of CYP1A2- Fluvoxamine and Decreased bioavailability- Activated charcoal, 2) Potential for olanzapine to affect other medicinal products- Olanzapine may antagonise the effects of direct and indirect dopamine agonists, Olanzapine showed no interaction when co-administered with lithium or biperiden.3) General CNS activity 4) QTc interval- Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval.

ADVERSE REACTIONS: Somnolence, eosinophilia, leukopenia, neutropenia, thrombocytopenia, respiratory depression, hypotension, bradycardia, sudden cardiac death, tachycardia, syncope, sinus pause, injection site reaction, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels, Epistaxis, glucosuria, increased appetite, dizziness, akathisia, parkinsonism, dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic-aminotransferases, rash, asthenia, fatigue, oedema, allergic reaction, hypothermia, dystonia, tardive dyskinesia, ventricular tachycardia, fibrillation, elevated lipid levels, akathisia, dyskinesia, parkinsonism, Salivary hypersecretion, Alopecia, constipation, Urinary incontinence, urinary retention, Amenorrhea, Breast enlargement, Asthenia, Fatigue, Oedema, Pyrexia dry mouth, photosensitivity reaction, rhabdomyolysis, drug withdrawal syndrome neonatal, Urinary incontinence, urinary retention, Urinary, Amenorrhea, Breast enlargement, Galactorrhea in females, Gynaecomastia/breast enlargement in males, Asthenia, Fatigue, Oedema, Pyrexia and priapism.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ TOLAZ DT 2.5,5,7.5,10 mg /MAY-22/02/ABPI
(Additional information is available on request)